Ikena Oncology, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 68.77 million compared to USD 34.12 million a year ago. Basic loss per share from continuing operations was USD 1.9 compared to USD 1.22 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.43 USD | +2.14% | +10.85% | -27.41% |
13/05 | Ikena Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
12/03 | Ikena Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.41% | 69.01M | |
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+28.31% | 12.16B | |
+24.73% | 12.17B |
- Stock Market
- Equities
- IKNA Stock
- News Ikena Oncology, Inc.
- Ikena Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022